Table 4.
Common adverse effects and their incidence at 26 weeks from five studies | |||
---|---|---|---|
Side effect | Incidence in % | ||
| |||
Placebo | Canagliflozin 100 mg | Canagliflozin 300 mg | |
| |||
Volume depletion | 0.68 | 0.87 | 1.63 |
Osmotic diuresis | 0.95 | 5.09a | 5.09a |
| |||
Genital mycotic infection | |||
| |||
Overall | 1.63 | 6.17a | 6.5a |
Male | 0.51 | 3.65a | 2.88a |
Female | 2.9 | 8.75a | 9.98a |
Note:
P<0.05. Data from Xiong et al.21